Cardlytics stock fell 4.17 percent as CEO sold shares

Published on 10/04/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardlytics stock was last at USD 2.53 on Nasdaq on October 2, 2026, after CEO Amit Gupta sold 7,382 shares at USD 2.533. Q2 revenue was USD 36.88 million versus USD 37.00 million consensus.

CDLX, US14161W1053, Illustration mit AI erstellt.

Cardlytics stock (ISIN US14161W1053) fell 4.17 percent to USD 2.53 on Nasdaq on October 2, 2026, leaving the company with a market capitalization of USD 14.7 million. The move followed CEO Amit Gupta's sale of 7,382 shares at a weighted average price of USD 2.533, according to Investing.com on October 2, 2026.

CEO sale meets weak chart

The transaction came after a sharp retreat in the shares. Cardlytics was last at USD 2.53 at 4:00 p.m. ET on October 2, 2026, while its 52-week range stood at USD 2.47 to USD 26.70 and volume reached 75,648 shares.

The price was 2.43 percent above the 52-week low, calculated from USD 2.53 against USD 2.47. The reference point matters because the stock's market value has fallen to USD 14.7 million, a level that leaves individual filings capable of moving the investment narrative.

Revenue missed by USD 0.12 million

Cardlytics reported USD 36.88 million in Q2 2026 revenue and diluted EPS of negative USD 1.50, according to InsiderTrades.com on October 3, 2026. Revenue was below the USD 37.00 million consensus cited for the quarter, while EPS beat the USD 2.30 loss consensus by USD 0.80 on the reported figures.

That mix gives investors two different signals. The revenue comparison points to limited top-line momentum, while the EPS comparison indicates that the loss was narrower than analysts had expected for Q2 2026.

Consensus stays above the market

MarketScreener listed a Hold consensus from four analysts on September 20, 2026, with an average 12-month price target of USD 6.00 and a last close of USD 3.44. The target was 137.2 percent above the USD 2.53 reference price used here, although the consensus date and the October 2 market level are different.

Cardlytics also carries a legal-cost overhang from its Bridg acquisition. In a filing dated September 4, 2026, the company disclosed a USD 6.4 million settlement with Bridg founder Amit Jain against a USD 6.5 million accrual, as reported in the SEC filing.

Cardlytics stock stays near its low

Cardlytics stock was last at USD 2.53 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 4.17 percent for the session. The Nasdaq listing and CDLX trading symbol are identified in the company's September 4, 2026 filing.